Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer

Abstract

MicroRNAs (miRNAs) are short, non‑coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs have potential as cancer biomarkers. The main objective of the present study was to assess the effect of miRNA‑23b (miR‑23b) expression in plasma on the diagnosis and prognosis of colorectal cancer (CRC). Reverse transcription‑quantitative polymerase chain reaction (PCR) was used to measure miR‑23b expression levels, and methylation‑specific PCR was used to test the promoter methylation status. Subsequently, the expression level of miR‑23b in plasma samples was compared between CRC patients and healthy control individuals. The miR‑23b expression levels were significantly lower in CRC cells and primary CRC tissues than in nonmalignant colorectal tissues (P<0.001). It was also shown that miR‑23b expression is downregulated by promoter methylation and can be restored by demethylation agent treatment. miR‑23b was significantly decreased in plasma samples from CRC patients compared with the healthy control individuals (P<0.001). The value of the area under the receiver operating characteristic curve was 0.842 (sensitivity, 84.38%; specificity, 77.08%; 95% confidence interval, 0.763‑0.922). Low plasma miR‑23b expression was significantly associated with clinical stage, tumor depth, distant metastasis and tumor recurrence. CRC patients with low miR‑23b expression in plasma exhibited a shorter recurrence‑free survival time and poorer overall survival rate. The present results suggested that the downregulation of miR‑23b in the plasma has the potential to be a diagnostic and prognostic biomarker in CRC.